|
|
|
|
||
ARQL $6.66Jan. 17, 2012, 11:52 a.m. EST Arqule rallies 20% on drug study Stories You Might Like * Sponsored: this site From now on, in Europe, everything gets worse * Sponsored: this site Using recent weeks to predict rest of 2012 * Sponsored: Top Stock Analysts These 3 Stocks Are “Lifetime Income Generators” [?] 0 Comments Share * Digg * Yahoo! Buzz * MySpace * del.icio.us * Fark * StumbleUpon * Newsvine By Val Brickates Kennedy ARQL 7.50 7.00 6.50 6.00 5.50 8a 9a 10a 11a 12p 1p 2p 3p BOSTON (MarketWatch) -- Shares of Arqule Inc. /quotes/zigman/61118/quotes/nls/arql ARQL +11.75% rallied 20% to $7.20 Tuesday after the biotech group reported positive results from a Phase II clinical study for its liver cancer treatment tivantinib. Arqule tested the product as a single-agent therapy in patients with hepatocellular carcinoma, the most common form of the disease, who had not responded well to previous therapies. |
return to message board, top of board |